In the 38-week study , 662 patients stabilized on oral aripiprazole were randomized to receive aripiprazole once-monthly 400mg ( n = 265 ) , oral aripiprazole ( n = 266 ) , or aripiprazole once-monthly 50mg ( subtherapeutic dose ; n = 131 ) .